Phase 2RecruitingPriority 3 · Moderate priorityNCT02859402
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
Plain-language summary
This Phase 2 trial is evaluating Busulfan and Fludarabine as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 19 Years to 65 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Busulfan (DRUG): intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5) | Fludarabine (DRUG): intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)
- Drugs / treatments
- Busulfan, Fludarabine
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details